ROCKWELL MEDICAL, INC. 8-K

What Happened
Rockwell Medical, Inc. (RMTI) filed a Form 8-K on June 15, 2026 reporting the results of its 2026 Annual Meeting held June 12, 2026. Stockholders elected two Class II directors (Joseph Dawson and Joan Lau, Ph.D.), approved the advisory vote on named executive officer compensation, ratified EisnerAmper LLP as the company’s independent registered public accounting firm for 2026, and approved an amendment to the Certificate of Incorporation to effect a reverse stock split.

Key Details

• Director elections (Class II, three-year terms to 2029):
  • Joseph Dawson — For: 9,812,114; Against: 869,022; Abstain: 330,731; Broker non-votes: 12,801,839.
  • Joan Lau, Ph.D. — For: 9,890,379; Against: 729,615; Abstain: 391,873; Broker non-votes: 12,801,839.
• Advisory compensation vote (non-binding): For: 8,232,918; Against: 2,682,354; Abstain: 96,595; Broker non-votes: 12,801,839 — approved on an advisory basis.
• Auditor ratification: EisnerAmper LLP ratified — For: 22,996,530; Against: 698,744; Abstain: 118,432.
• Reverse stock split amendment: Approved — For: 16,993,038; Against: 6,597,036; Abstain: 223,632.

Why It Matters
These outcomes confirm the company’s governance slate and corporate actions authorized by shareholders. The advisory approval of executive compensation is non-binding but signals investor sentiment on pay. Ratification of EisnerAmper LLP establishes the auditor for 2026. Approval of the reverse stock split amendment means Rockwell can proceed with consolidating shares per the adopted charter change (which, if implemented, will reduce share count and raise the per‑share price proportionally). Investors should watch for a subsequent announcement with the split ratio and effective date, as well as any impacts on liquidity and outstanding share count.